亚洲 · 区域市场 · Pulse (Maeil Business)
Samsung Bioepis signs $420 mn U.S. biosimilar deal with Teva
Samsung Bioepis has signed a U.S. commercialization agreement worth up to $420 million with global pharmaceutical company Teva, expanding its presence in the world’s largest…
在 Pulse (Maeil Business) 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (pulse.mk.co.kr)
